Health and Healthcare
What to Expect When Mylan Reports Tuesday
Published:
Last Updated:
Mylan N.V. (NASDAQ: MYL) is scheduled to release its first-quarter financial results before the markets open on Tuesday. The consensus forecast calls for $0.79 in earnings per share (EPS) and $2.7 billion in revenue. The same period of last year reportedly had EPS of $0.96 on $2.68 billion in revenue.
This past quarter, Mylan obtained approval to market its generic inhaler in three strengths. The Advair Diskus is marketed by GlaxoSmithKline PLC (NYSE: GSK), and this is far from being a small drug. Advair sales had been declining over time to about $3.1 billion globally in 2017, but the sales were over $5 billion in 2013. The website Statista showed that U.S. Advair sales were $1.6 billion in 2017.
Chronic lung diseases are serious issues for America and elsewhere. In the United States alone, over 26 million people are known to have asthma, and about 7 million of them are children. Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that makes it hard to breathe and may become worse over time, and sadly there is no cure.
COPD can become debilitating and fatal over time. According to the American Lung Association, COPD is the third leading cause of death in the United States and more than 11 million people have been diagnosed with COPD. Sadly, the group warned that millions more may have the disease without even knowing it.
Excluding Monday’s move, Mylan had underperformed the broad markets, with its stock up about 2% year to date. In the past 52 weeks, the stock was actually up 24%.
A few analysts weighed in on Mylan ahead of the report:
- Cantor Fitzgerald has a Hold rating.
- Argus has a Buy rating with $32 price target
- SunTrust has a Buy rating and a $35 price target.
- UBS has a Neutral rating with a $31 price target.
- Credit Suisse has a Buy rating and a $37 target.
Shares of Mylan were last seen down less than 1% at $27.85, in a 52-week range of $26.00 to $42.50. The consensus price target is $35.94.
24/7 Wall St.The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
